<DOC>
	<DOCNO>NCT00650091</DOCNO>
	<brief_summary>Idiopathic pulmonary fibrosis ( IPF ) long-term lung disease affect individual 's ability breathe . In randomized , double-blind , placebo-controlled trial , assign patient idiopathic pulmonary fibrosis mild-to-moderate lung-function impairment one three group — receive combination prednisone , azathioprine , NAC ( combination therapy ) , NAC alone , placebo — 1:1:1 ratio .</brief_summary>
	<brief_title>Evaluating Effectiveness Prednisone , Azathioprine , N-acetylcysteine Patients With IPF</brief_title>
	<detailed_description>IPF disease widespread permanent scar lung tissue eventually result death . Individuals IPF may experience breathe difficulty , cough , chest pain , decrease exercise capacity . Although cause IPF unknown , may result inflammatory response unknown substance . NAC , antioxidant effective loosening mucus form lung , may improve lung function . The purpose study evaluate effectiveness NAC preventing loss lung function people IPF . In initial double-blind , placebo-controlled trial , subject idiopathic pulmonary fibrosis mild-to-moderate impairment pulmonary function randomly assign receive three-drug regimen prednisone , azathioprine , acetylcysteine ; acetylcysteine alone ; placebo . After safety concern identify data safety monitor board , three-drug regimen stop National Heart , Lung , Blood Institute ( NHLBI ) October 14 , 2011 , clinical alert issue . After brief period interruption modification protocol approval institutional review board , patient continue recruited acetylcysteine group placebo group follow pre-specified duration 60 week . Study visit occur baseline Weeks 4 , 15 , 30 , 45 , 60 . At study visit , physical exam blood collection occur . At select visit , follow study procedure occur : lung function testing ; urine collection ; 6-minute walk test , questionnaires assess health status , breathing , quality life . Participants record medication usage symptom daily diary .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Forced vital capacity ( FVC ) great equal 50 % predict value Diffusion capacity ( DLCO ) great equal 30 % predict value Diagnosis IPF modify American Thoracic Society ( ATS ) criteria 48 month study entry History clinically significant environmental exposure know cause pulmonary fibrosis Diagnosis connective tissue disease likely cause interstitial disease Extent emphysema great extent fibrotic change ( i.e. , honeycomb , reticular change ) high resolution compute tomography ( HRCT ) scan Forced expiratory volume 1 second ( FEV1 ) /FVC ratio le 0.65 time screening ( postbronchodilator ) Partial pressure arterial oxygen ( PaO2 ) less 55 mm Hg ( less 50 mm Hg Denver study site ) Residual volume great 120 % predicted time screen ( postbronchodilator ) Evidence active infection Significant bronchodilator response screen spirometry , define change FEV1 great equal 12 % absolute change great 200 mL OR change FVC great equal 12 % absolute change great 200 mL Screening baseline FVC measurement ( liter , postbronchodilator ) differ 11 % Listed lung transplantation History unstable deteriorate cardiac disease Heart attack , coronary artery bypass , angioplasty 6 month study entry Unstable angina pectoris congestive heart failure require hospitalization 6 month study entry Uncontrolled arrhythmia Severe uncontrolled high blood pressure Known HIV hepatitis C Known cirrhosis chronic active hepatitis Active substance and/or alcohol abuse Pregnant breastfeed Women childbearing potential use medically approve mean contraception Any clinically relevant lab abnormality , include follow : 1 . Creatinine great twice upper limit normal ( ULN ) 2 . Hematology outside specify limit 1 . White blood cell less 3,500/mm3 2 . Hematocrit le 25 % great 59 % 3 . Platelets le 100,000 mm3 time screen 3 . Any following liver function test criterion specify limit 1 . Total bilirubin great twice ULN 2 . Aspartate ( AST ) alanine aminotransferase ( ALT ) great 1.5 ULN 3 . Alkaline phosphatase great three time ULN 4 . Albumin le 3.0 mg/dL time screen Known hypersensitivity study medication Any condition IPF , opinion site PI , likely result death 1 year study entry Any condition , judgment PI , might cause participation study detrimental make person poor candidate study</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Idiopathic Pulmonary Fibrosis</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Azathioprine</keyword>
	<keyword>NAC</keyword>
	<keyword>N-acetylcysteine</keyword>
</DOC>